Clinical significance of tumor location in non-muscle-invasive bladder cancer: A single-center longitudinal cohort analysis

Background: Recurrence of non-muscle-invasive bladder cancer (NMIBC) still presents a significant clinical challenge, with the contributing factors yet to be fully understood. Objective: This study explored the clinical implications of tumor location in NMIBC recurrence. Methods: An observational cohort study was conducted, including 108 NMIBC patients who experienced a total of 344 NMIBC diagnoses (both primary and recurrent) between 1999 and 2019. Clinical information was collected for primary and recurrent tumors. Tumor locations were classified into 10 categories: bladder neck (neck), dome, posterior, anterior, trigone, right, right rear, left, multiple site(s), and others. The association between tumor location and recurrence was systematically analyzed. Results: The median follow-up period lasted for 28 months (range: 2–88 months), the median recurrence interval was 13.5 months, and 44 patients (40.7%) progressed into muscle-invasive disease. Univariate analysis revealed that tumor location within the bladder significantly impacted recurrence-free interval, progression-free survival, and overall survival. Tumors situated in the bladder neck, dome, right posterior wall, and trigone demonstrated significantly shorter recurrence-free intervals, rendering these areas high-risk regions. The original tumor site was the most common relapse location, and the recurrence interval shortened as the number of recurrences increased. Over time, the recurrence pattern shifted, with tumors most frequently recurring in the left wall, multiple sites, right wall, and posterior wall. Conclusion: The findings suggest that bladder cancer most commonly recurs at the original site, with high-risk locations linked to shorter recurrent intervals and greater risks for disease progression. In addition, the recurrence interval tends to decrease with successive recurrences.
- Sjödahl G, Eriksson P, Patschan O, et al. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. Int J Cancer. 2019;146(9):2636-2647. doi: 10.1002/ijc.32737
- Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The dutch South-Eastern urological collaborative group. Br J Urol. 1994;73(4):403-408. doi: 10.1111/j.1464-410x.1994.tb07604.x
- Svatek RS, Clinton TN, Wilson CA, et al. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology. 2014;84(5):1147-1151. doi: 10.1016/j.urology.2014.05.011
- Vukomanovic I, Colovic V, Soldatovic I, Hadzi-Djokic J. Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer. Med Oncol. 2012;29(3):1916-1920. doi: 10.1007/s12032-011-9999-4
- Weiner AB, Desai AS, Meeks JJ. Tumor location may predict adverse pathology and survival following definitive treatment for bladder cancer: A national cohort study. Eur Urol Oncol. 2019;2(3):304-310. doi: 10.1016/j.euo.2018.08.018
- Nouhaud FX, Chakroun M, Lenormand C, et al. Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study. Urol Oncol. 2021;39(3):195.e1-e6. doi: 10.1016/j.urolonc.2020.09.006
- Schrier BP, Hollander MP, Van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle-invasive bladder cancer: Difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004;45(3):292-296. doi: 10.1016/j.eururo.2003.10.006
- Moschini M, Sharma V, Dell’Oglio P, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2016;117(4):604-610. doi: 10.1111/bju.13146
- Thomas F, Noon AP, Rubin N, Goepel JR, Catto JW. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol. 2013;63(1):145-154. doi: 10.1016/j.eururo.2012.08.064
- Stephenson WT, Holmes FF, Noble MJ, Gerald KB. Analysis of bladder carcinoma by subsite. Cystoscopic location may have prognostic value. Cancer. 1990;66(7):1630-165. doi: 10.1002/1097-0142(19901001)66:7<1630:aid-cncr2820660730>3.0.co;2-7
- Kobayashi S, Fujii Y, Koga F, et al. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: A prospective validation study. Urol Oncol. 2014;32(1):38.e29-e36. doi: 10.1016/j.urolonc.2013.04.001
- Fujii Y, Fukui I, Kihara K, et al. Significance of bladder neck involvement on progression in superficial bladder cancer. Eur Urol. 1998;33(5):464-468. doi: 10.1159/000019636
- Martin M, Bernardini S, Kleinclauss F, Della Negra E, Henry PC, Bittard H. Prognostic value of tumor location of urothelial tumors of the bladder, after total cystectomy. Prog Urol. 2002;12(6):1221-1227.
- Fowler JC, King C, Bryant C, et al. Selection of oncogenic mutant clones in normal human skin varies with body site. Cancer Discov. 2021;11(2):340-361. doi: 10.1158/2159-8290.cd-20-1092
- Kim K, Cho Y, Sohn JH, et al. Clinicopathologic characteristics of early gastric cancer according to specific intragastric location. BMC Gastroenterol. 2019;19(1):1-8. doi: 10.1186/s12876-019-0949-5
- Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: A systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211-219. doi: 10.1001/jamaoncol.2016.4227
- Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168-2179. doi: 10.1016/S0140-6736(13)61903-0
- Tang Q, Lian Y, Yu J, Wang Y, Shi Z, Chen L. Anatomic mapping of molecular subtypes in diffuse glioma. BMC Neurol. 2017;17(1):183. doi: 10.1186/s12883-017-0961-8
- Tang J, Fewings E, Chang D, et al. The genomic landscapes of individual melanocytes from human skin. Nature. 2020;586(7830):600-605. doi: 10.1038/s41586-020-2785-8
- Weiss JM, Hunter MV, Cruz NM, et al. Anatomic position determines oncogenic specificity in melanoma. Nature. 2022;604(7905):354-361. doi: 10.1038/s41586-022-04584-6